Molecular Dx

These ten governments have committed funding for projects that will sequence a minimum of 100,000 citizens to spur genomic medicine

If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark...

10 privately-held diagnostics developers primarily focused on liquid biopsy tests, ranked by total money raised from venture capital firms.

The nation’s largest private health insurer, UnitedHealthcare, announced August 1 that it will cover testing that will allow physicians to match their patients to...

It would be hard to find an area of health where the microbiome has not been implicated as a major player. The microbiome is...

The companies will partner on a proof-of-concept project focused on detection of SARS-CoV-2 coronavirus as the first initiative of a broader collaboration focused on developing molecular diagnostic tests for infectious diseases and oncology.

Scripps researchers compare available genome sequence data for known coronavirus strains to determine that that SARS-CoV-2 originated through natural processes and note that their results “clearly show that SARS-CoV-2 is not a laboratory construct or a purposefully manipulated virus.”

GenapSys’ sequencing system is about the size of an iPad, costs under $10,000, and is based on a proprietary direct electronic sequencing chip, which is intended to eliminate the need for cumbersome equipment.

A study of 191 patients—137 survivors and 54 non-survivors—from two hospitals in Wuhan, China showed key risk factors for death were advanced age, signs of sepsis, and blood clotting issues.

The study used four adult Chinese rhesus macaques and found that those monkeys that had been re-exposed to SARS-CoV-2, like the unexposed control monkey, showed no recurrence of COVID-19.